Metabolic Syndrome in Adults from 20 to 40 Years Old in a Rural Mexican Community

Mauro Echavarría-Pinto; Adrián Hernández-Lomelí; Marco Antonio Alcocer-Gamba; Héctor Morales-Flores; Alberto Vázquez-Mellado

2006, Number 4

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2006; 44 (4)

Metabolic Syndrome in Adults from 20 to 40 Years Old in a Rural Mexican Community

Echavarría-Pinto M, Hernández-Lomelí A, Alcocer-Gamba MA, Morales-Flores H, Vázquez-Mellado A

Full text

How to cite this article

Language: Spanish
References: 19
Page: 329-335
PDF size: 100.25 Kb.

ABSTRACT

Introduction: Metabolic syndrome is the main health problem in Mexico. Its two principal complications (ischemic cardiopathy and type-2 diabetes) are the two main causes of death in Mexico since 2000.
Objective: To describe the prevalence of the metabolic syndrome in adults from 20 to 40 years old in a Mexican rural community (Senegal de Palomas, San Juan del Río, Querétaro) using the National Cholesterol Education Program (NCEP III) definition.
Material and methods: A descriptive study with a random sample was carried out. We present a univariate analysis with a 95 % confidence interval.
Results: 73 cases were studied. The prevalence of the metabolic syndrome was 45.2 % slightly higher in men (48.4 %) than in women (42.8 %). The prevalence of hypertension was 27.3 %. The prevalence of obesity was 26.1 % using the definition of the WHO and this prevalence rises up to 49.4 % using the definition of the Mexican Official Norm. 90.5 % of women and 93.5 % of men had low HDLc.
Conclusions: The prevalence of metabolic syndrome in adults from 20 to 40 years old in this Mexican rural community is much higher than the national mean for the same age cohort. The results show the necessity to increase the research of our rural communities in order to identify the possible causes to this problem and to create therapeutic programs for patients with metabolic syndrome.

REFERENCES

1. Aguilar-Salinas CA, Rojas R, Gómez-Pérez FJ, Franco A, Olaiz G, Rull JA, Sepúlveda J. El síndrome me-tabólico: un concepto en evolución. Gac Med Mex 2004;140(2):s41-s48.
2. Garber AJ. The metabolic syndrome. Med Clin North Am 2004;88(4):837-846.
3. Darwin-Deen. Metabolic syndrome: time for action. Am Fam Physician 2004;69:12.
4. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its com-plications. Report of a WHO consultation. Geneva: WHO; 1999.
5. National Heart, Lung and Blood Institute. Cho-lesterol Education Program. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treat-ment Panel III). Disponible en: http://www.nhlbi. nih.gov/guidelines/cholesterol/atp3_rpt.htm
6. Balkau B, Charles MA, Drivsholm T, Borch-Jhonsen K, Wareham N. European Group for the Study of Insulin Resistance (EGIR): frequency of the WHO metabolic syndrome in European cohorts, and the alternative definition of an insulin resistance syn-drome. Diabetes Metab 2002;28:364-376.
7. Bloomgarden ZT. American Association of Clinical Endocrinologists (AACE) Consensus, Conference on the Insulin Resistance Syndrome, 25-26 august 2002, Washington, DC. Diabetes Care 2003;26: 1297-1303.
8. International Diabetes Federation. The IDF consen-sus worldwide definition of the metabolic syndrome. April 14, 2005. Disponible en: http://www.idf.org/webdata/docs/Metac_syndrome_def.pdf
9. Lerman-Garber I, Aguilar-Salinas CA, Gómez-Pérez FJ, Reza-Albarrán A, Hernández-Jiménez S, Vázquez-Chávez C, Rull JA. El síndrome metabólico, posición de la sociedad mexicana de nutrición y endocri-nología, sobre la definición, fisiopatología y diag-nóstico. Características del síndrome metabólico en México. Rev Endocrinol Nutr 2004;12(3):109-122.
Aguilar-Salinas CA, Rojas R , Gómez-Pérez FJ, Valles V, Ríos-Torres JM, Franco A, et al. High prevalence of metabolic syndrome in México. Arch Med Res 2004;35:76-81.
Cameron AJ, Shaw JE, Zimmet P. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin 2004;33:2.
Aguilar-Salinas CA, Rojas R, Gómez-Pérez FJ, García E, Valles V, Ríos-Torres JM, et al. Charac-teristics of patients with type 2 diabetes in Mexico. Diabetes Care 2003;26: 2021-2026.
Carnevale-Schianca GP, Rossi A, Sainaghi PP, Maduli E, Bartoli E. The significance of impaired fasting glucose versus impaired glucose tolerance: importance of insulin secretion and resistance. Diabetes Care 2003;26:1333-1337.
Subsecretaría de Prevención de la Salud, Centro Nacional de Vigilancia Epidemiológica, Programa de Salud del Adulto y del Anciano. Cuestionario de factores de riesgo. Disponible en: http://www. salud.gob.mx/unidades/cdi/documentos/diabetes_ mellitus.pdf
Secretaría de Salud. Norma oficial mexicana NOM-174-SSA1-1998, para el manejo integral de la obe-sidad. Rev Med IMSS 2000;38(5):397-403.
Sepúlveda J. Encuesta Nacional de Salud 2000 (ENSA 2000). México: Instituto Nacional de Salud Pública; 2000.
Aguilar-Salinas CA, Olaiz G, Valles V, Ríos-Torres JM, Gómez-Pérez FJ, Rull JA, et al. High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican national survey. J Lipid Res 2001;42: 1298-1307.
Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am 2004;33(2):283-303.
Natali A, Ferrannini E. Hypertension, insulin re-sistance, and the metabolic syndrome. Endocrinol Metab Clin North Am 2004; 33(2):417-429.